This article examines rebif adverse reactions and its clinical applications in MS treatment. Clinical trial data from large patient populations provide evidence of efficacy and safety profiles. The study identifies important adverse effects and contraindications that clinicians must monitor during treatment. Treatment optimization models can help predict which patients will benefit most from these medications. Both benefits and potential risks must be carefully communicated to patients during treatment selection.
